These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 19770361)

  • 1. Recombinant canine B-domain-deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model.
    Sabatino DE; Freguia CF; Toso R; Santos A; Merricks EP; Kazazian HH; Nichols TC; Camire RM; Arruda VR
    Blood; 2009 Nov; 114(20):4562-5. PubMed ID: 19770361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotype correction of hemophilia A mice with adeno-associated virus vectors carrying the B domain-deleted canine factor VIII gene.
    Ishiwata A; Mimuro J; Kashiwakura Y; Niimura M; Takano K; Ohmori T; Madoiwa S; Mizukami H; Okada T; Naka H; Yoshioka A; Ozawa K; Sakata Y
    Thromb Res; 2006; 118(5):627-35. PubMed ID: 16371232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A.
    Nguyen GN; George LA; Siner JI; Davidson RJ; Zander CB; Zheng XL; Arruda VR; Camire RM; Sabatino DE
    J Thromb Haemost; 2017 Jan; 15(1):110-121. PubMed ID: 27749002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype.
    Siner JI; Iacobelli NP; Sabatino DE; Ivanciu L; Zhou S; Poncz M; Camire RM; Arruda VR
    Blood; 2013 May; 121(21):4396-403. PubMed ID: 23372167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs.
    Jiang H; Lillicrap D; Patarroyo-White S; Liu T; Qian X; Scallan CD; Powell S; Keller T; McMurray M; Labelle A; Nagy D; Vargas JA; Zhou S; Couto LB; Pierce GF
    Blood; 2006 Jul; 108(1):107-15. PubMed ID: 16522813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A.
    Brown BD; Shi CX; Powell S; Hurlbut D; Graham FL; Lillicrap D
    Blood; 2004 Feb; 103(3):804-10. PubMed ID: 14512318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soy Phosphatidylinositol-Containing Lipid Nanoparticle Prolongs the Plasma Survival and Hemostatic Efficacy of B-domain-Deleted Recombinant Canine Factor VIII in Hemophilia A Dogs.
    Shetty KA; Merricks EP; Raymer R; Rigsbee N; Nichols TC; Balu-Iyer SV
    J Pharm Sci; 2016 Aug; 105(8):2459-64. PubMed ID: 27372547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and characterization of recombinant ovine coagulation factor VIII.
    Zakas PM; Gangadharan B; Almeida-Porada G; Porada CD; Spencer HT; Doering CB
    PLoS One; 2012; 7(11):e49481. PubMed ID: 23152911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver-restricted expression of the canine factor VIII gene facilitates prevention of inhibitor formation in factor VIII-deficient mice.
    Ishiwata A; Mimuro J; Mizukami H; Kashiwakura Y; Takano K; Ohmori T; Madoiwa S; Ozawa K; Sakata Y
    J Gene Med; 2009 Nov; 11(11):1020-9. PubMed ID: 19757487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice.
    Shetty KA; Kosloski MP; Mager DE; Balu-Iyer SV
    Biopharm Drug Dispos; 2016 Oct; 37(7):409-420. PubMed ID: 27418232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the biological differences of canine and human factor VIII in gene delivery: implications in human hemophilia treatment.
    Wang Q; Dong B; Firrman J; Wu W; Roberts S; Moore AR; Liu LS; Chin MP; Diao Y; Kost J; Xiao W
    Gene Ther; 2016 Jul; 23(7):597-605. PubMed ID: 27064790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term follow-up of liver-directed, adeno-associated vector-mediated gene therapy in the canine model of hemophilia A.
    Batty P; Mo AM; Hurlbut D; Ishida J; Yates B; Brown C; Harpell L; Hough C; Pender A; Rimmer EK; Sardo Infirri S; Winterborn A; Fong S; Lillicrap D
    Blood; 2022 Dec; 140(25):2672-2683. PubMed ID: 35405003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soy phosphatidylinositol containing nanoparticle prolongs hemostatic activity of B-domain deleted factor VIII in hemophilia A mice.
    Shetty KA; Kosloski MP; Mager DE; Balu-Iyer SV
    J Pharm Sci; 2015 Feb; 104(2):388-95. PubMed ID: 24700333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of factor VIII transgenes bioengineered for improved expression in gene therapy of hemophilia A.
    Dooriss KL; Denning G; Gangadharan B; Javazon EH; McCarty DA; Spencer HT; Doering CB
    Hum Gene Ther; 2009 May; 20(5):465-78. PubMed ID: 19222367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of the immune response to factor VIII mediated through tolerogenic factor VIII presentation by immature dendritic cells.
    Qadura M; Othman M; Waters B; Chegeni R; Walker K; Labelle A; Ozelo M; Hough C; Lillicrap D
    J Thromb Haemost; 2008 Dec; 6(12):2095-104. PubMed ID: 18826393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models.
    Siner JI; Samelson-Jones BJ; Crudele JM; French RA; Lee BJ; Zhou S; Merricks E; Raymer R; Nichols TC; Camire RM; Arruda VR
    JCI Insight; 2016 Oct; 1(16):e89371. PubMed ID: 27734034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII.
    Zollner SB; Raquet E; Müller-Cohrs J; Metzner HJ; Weimer T; Pragst I; Dickneite G; Schulte S
    Thromb Res; 2013 Aug; 132(2):280-7. PubMed ID: 23830969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy.
    Finn JD; Ozelo MC; Sabatino DE; Franck HW; Merricks EP; Crudele JM; Zhou S; Kazazian HH; Lillicrap D; Nichols TC; Arruda VR
    Blood; 2010 Dec; 116(26):5842-8. PubMed ID: 20876851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy.
    Xu L; Nichols TC; Sarkar R; McCorquodale S; Bellinger DA; Ponder KP
    Proc Natl Acad Sci U S A; 2005 Apr; 102(17):6080-5. PubMed ID: 15837921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relevance of factor VIII (FVIII) pharmacokinetics to TDM and hemophilia a treatment: is B domain-deleted FVIII equivalent to full-length FVIII?
    Johnston A
    Ther Drug Monit; 2012 Feb; 34(1):110-7. PubMed ID: 22249347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.